{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:35:44Z","timestamp":1790789744226,"version":"4.1.0"},"reference-count":290,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022712","name":"Mark Hughes Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022712","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001771","name":"University of Newcastle Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jconrel.2024.05.018","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T11:56:40Z","timestamp":1716206200000},"page":"835-865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma"],"prefix":"10.1016","volume":"370","author":[{"given":"Lauren M.","family":"Arms","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Duchatel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangeline R.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Garcia","family":"Sobrinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Dun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.05.018_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114777","article-title":"From cells to organoids: the evolution of blood-brain barrier technology for modelling drug delivery in brain cancer","volume":"196","author":"Gonzales-Aloy","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"23","key":"10.1016\/j.jconrel.2024.05.018_bb0010","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.3390\/cancers13236099","article-title":"Childhood malignant brain tumors: balancing the bench and bedside","volume":"13","author":"Thorbinson","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2024.05.018_bb0015","series-title":"Australia\u2019s Children","author":"Health AIo, Welfare","year":"2022"},{"issue":"2","key":"10.1016\/j.jconrel.2024.05.018_bb0020","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.phoj.2023.02.003","article-title":"Diffuse intrinsic pontine glioma: insights into oncogenesis and opportunities for targeted therapy","volume":"8","author":"Groves","year":"2023","journal-title":"Pediatr. Hematol. Oncol. J."},{"issue":"4","key":"10.1016\/j.jconrel.2024.05.018_bb0025","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s10555-019-09824-2","article-title":"Pediatric diffuse intrinsic pontine glioma: where do we stand?","volume":"38","author":"Rashed","year":"2019","journal-title":"Cancer Metastasis Rev."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0030","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1038\/s41598-023-30395-4","article-title":"Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes","volume":"13","author":"Ajuyah","year":"2023","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.jconrel.2024.05.018_bb0035","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccr.2013.10.006","article-title":"Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas","volume":"24","author":"Bender","year":"2013","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14728222.2023.2177531","article-title":"H3K27-altered diffuse midline glioma: a paradigm shifting opportunity in direct delivery of targeted therapeutics","volume":"27","author":"Rechberger","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"issue":"8","key":"10.1016\/j.jconrel.2024.05.018_bb0045","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"issue":"8","key":"10.1016\/j.jconrel.2024.05.018_bb0050","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11940-019-0577-y","article-title":"Diffuse intrinsic pontine glioma: from diagnosis to next-generation clinical trials","volume":"21","author":"Vitanza","year":"2019","journal-title":"Curr. Treat. Options Neurol."},{"issue":"11","key":"10.1016\/j.jconrel.2024.05.018_bb0055","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1158\/2159-8290.CD-23-0131","article-title":"Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways","volume":"13","author":"Venneti","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0060","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3389\/fonc.2018.00239","article-title":"Beyond the Blood:Brain Barrier: The Importance of Central Nervous System (CNS) Pharmacokinetics for the Treatment of CNS Tumors, Including Diffuse Intrinsic Pontine Glioma","volume":"8","author":"Warren","year":"2018","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.jconrel.2024.05.018_bb0065","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","article-title":"Drug transport across the blood-brain barrier","volume":"32","author":"Pardridge","year":"2012","journal-title":"J. Cerebr. Blood Flow Metabol.\u202f: Off. J. Int. Soc. Cerebr. Blood Flow Metabol."},{"issue":"6","key":"10.1016\/j.jconrel.2024.05.018_bb0070","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.7150\/thno.21254","article-title":"Current strategies for brain drug delivery","volume":"8","author":"Dong","year":"2018","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0075","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","article-title":"A blood\u2013brain barrier overview on structure, function, impairment, and biomarkers of integrity","volume":"17","author":"Kadry","year":"2020","journal-title":"Fluid. Barr. CNS."},{"issue":"9","key":"10.1016\/j.jconrel.2024.05.018_bb0080","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/neuonc\/noac117","article-title":"The intrinsic and microenvironmental features of diffuse midline glioma: implications for the development of effective immunotherapeutic treatment strategies","volume":"24","author":"Persson","year":"2022","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0085","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2024.05.018_bb0090","first-page":"17","article-title":"The neurovascular unit in diffuse intrinsic pontine gliomas","volume":"2","author":"El-Khouly","year":"2021","journal-title":"Free Neuropathol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0095","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood\u2013brain barrier: structure, regulation, and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.jconrel.2024.05.018_bb0100","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ccell.2017.03.011","article-title":"Transcriptional dependencies in diffuse intrinsic pontine glioma","volume":"31","author":"Nagaraja","year":"2017","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.jconrel.2024.05.018_bb0105","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1038\/s41588-022-01236-3","article-title":"The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location","volume":"54","author":"Liu","year":"2022","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3389\/fonc.2012.00205","article-title":"Diffuse intrinsic pontine glioma: poised for progress","volume":"2","author":"Warren","year":"2012","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0115","series-title":"World Health Organisation Classification of Tumours of the Central Nervous System","first-page":"15","article-title":"Gliomas, glioneuronal tumours, and neuronal tumours","author":"Varlet","year":"2021"},{"key":"10.1016\/j.jconrel.2024.05.018_bb0120","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00401-014-1319-6","article-title":"Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications","volume":"128","author":"Buczkowicz","year":"2014","journal-title":"Acta Neuropathol."},{"issue":"19","key":"10.1016\/j.jconrel.2024.05.018_bb0125","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2017.75.9308","article-title":"Clinical, radiologic, pathologic, and molecular characteristics of Long-term survivors of diffuse intrinsic pontine glioma (DIPG): a collaborative report from the international and European Society for Pediatric Oncology DIPG registries","volume":"36","author":"Hoffman","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0130","doi-asserted-by":"crossref","first-page":"11628","DOI":"10.1038\/ncomms11628","article-title":"Identification of proliferative progenitors associated with prominent postnatal growth of the pons","volume":"7","author":"Lindquist","year":"2016","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.jconrel.2024.05.018_bb0135","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3390\/jpm12050840","article-title":"Diffuse intrinsic pontine glioma: molecular landscape, evolving treatment strategies and emerging clinical trials","volume":"12","author":"Damodharan","year":"2022","journal-title":"J. Personaliz. Med."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0140","doi-asserted-by":"crossref","first-page":"1016343","DOI":"10.3389\/fonc.2022.1016343","article-title":"Inter and intra-tumor heterogeneity of paediatric type diffuse high-grade gliomas revealed by single-cell mass cytometry","volume":"12","author":"Petrilli","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40478-015-0269-0","article-title":"Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics","volume":"4","author":"Hoffman","year":"2016","journal-title":"Acta Neuropathol. Commun."},{"issue":"9","key":"10.1016\/j.jconrel.2024.05.018_bb0150","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1097\/PAS.0b013e318294e817","article-title":"Morphologic characteristics and immunohistochemical profile of diffuse intrinsic pontine gliomas","volume":"37","author":"Ballester","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"issue":"8","key":"10.1016\/j.jconrel.2024.05.018_bb0155","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/emmm.201101131","article-title":"Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives","volume":"4","author":"Saunders","year":"2012","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0160","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00401-012-0998-0","article-title":"K27M mutation in histone H3. 3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas","volume":"124","author":"Khuong-Quang","year":"2012","journal-title":"Acta Neuropathol."},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0165","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3171\/2018.9.PEDS18419","article-title":"Impact of the H3K27M mutation on survival in pediatric high-grade glioma: a systematic review and meta-analysis","volume":"23","author":"Lu","year":"2018","journal-title":"J. Neurosurg. Pediatr."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.742561","article-title":"Emerging advances in combinatorial treatments of epigenetically altered pediatric high-grade H3K27M gliomas","volume":"12","author":"Leszczynska","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0175","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3389\/fphar.2017.00495","article-title":"Potential new therapies for pediatric diffuse intrinsic pontine glioma","volume":"8","author":"Long","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0180","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/ng.1102","article-title":"Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas","volume":"44","author":"Wu","year":"2012","journal-title":"Nat. Genet."},{"issue":"7384","key":"10.1016\/j.jconrel.2024.05.018_bb0185","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10833","article-title":"Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma","volume":"482","author":"Schwartzentruber","year":"2012","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jconrel.2024.05.018_bb0190","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41388-021-02102-y","article-title":"Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies","volume":"41","author":"Findlay","year":"2022","journal-title":"Oncogene"},{"issue":"21\u221222","key":"10.1016\/j.jconrel.2024.05.018_bb0195","article-title":"Signal transduction in diffuse intrinsic pontine glioma","volume":"19","author":"Duchatel","year":"2019","journal-title":"Proteomics"},{"key":"10.1016\/j.jconrel.2024.05.018_bb0200","article-title":"A review of the anti-tumor potential of current therapeutics targeting the mitochondrial protease ClpP in H3K27-altered, diffuse midline glioma","volume":"noad144","author":"Jackson","year":"2023","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jconrel.2024.05.018_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2015.00147","article-title":"Pathology, molecular genetics, and epigenetics of diffuse intrinsic pontine glioma","volume":"5","author":"Buczkowicz","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0210","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3389\/fonc.2015.00148","article-title":"Future clinical trials in DIPG: bringing epigenetics to the clinic","volume":"5","author":"Morales La Madrid","year":"2015","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.jconrel.2024.05.018_bb0215","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO.2009.25.5463","article-title":"Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets","volume":"28","author":"Zarghooni","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"5\u20136","key":"10.1016\/j.jconrel.2024.05.018_bb0220","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1089\/ten.tea.2020.0110","article-title":"Matrix stiffness modulates patient-derived glioblastoma cell fates in three-dimensional hydrogels","volume":"27","author":"Wang","year":"2021","journal-title":"Tissue Eng. Part A"},{"key":"10.1016\/j.jconrel.2024.05.018_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100898","article-title":"Leptomeningeal dissemination in pediatric brain tumors","volume":"39","author":"Cocito","year":"2023","journal-title":"Neoplasia"},{"issue":"6","key":"10.1016\/j.jconrel.2024.05.018_bb0230","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/CCO.0000000000000577","article-title":"Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets","volume":"31","author":"Aziz-Bose","year":"2019","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0235","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3389\/fonc.2015.00237","article-title":"DIPG in children - what can we learn from the past?","volume":"5","author":"Vanan","year":"2015","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0240","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2017.10.013","article-title":"Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG)","volume":"120","author":"Gwak","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.jconrel.2024.05.018_bb0245","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/neuonc\/noq205","article-title":"Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children\u2019s oncology group","volume":"13","author":"Cohen","year":"2011","journal-title":"Neuro-Oncology"},{"issue":"2","key":"10.1016\/j.jconrel.2024.05.018_bb0250","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11060-011-0681-7","article-title":"Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma","volume":"106","author":"Chassot","year":"2012","journal-title":"J. Neuro-Oncol."},{"issue":"7","key":"10.1016\/j.jconrel.2024.05.018_bb0255","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrclinonc.2012.87","article-title":"Paediatric and adult malignant glioma: close relatives or distant cousins?","volume":"9","author":"Jones","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"30","key":"10.1016\/j.jconrel.2024.05.018_bb0260","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1200\/JCO.2011.35.5677","article-title":"Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma","volume":"29","author":"Paugh","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2024.05.018_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030313","article-title":"Mesenchymal transition and PDGFRA amplification\/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas","volume":"7","author":"Puget","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jconrel.2024.05.018_bb0270","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/ng.2938","article-title":"The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma","volume":"46","author":"Wu","year":"2014","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.jconrel.2024.05.018_bb0275","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1586\/ecp.11.1","article-title":"Corticosteroids in brain cancer patients: benefits and pitfalls","volume":"4","author":"Dietrich","year":"2011","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0280","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s11060-016-2141-x","article-title":"State of affairs in use of steroids in diffuse intrinsic pontine glioma: an international survey and a review of the literature","volume":"128","author":"Veldhuijzen van Zanten","year":"2016","journal-title":"J. Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0285","article-title":"Does a bevacizumab-based regime have a role in the treatment of children with diffuse intrinsic pontine glioma? A systematic review","volume":"4","author":"Evans","year":"2022","journal-title":"Neurooncol Adv."},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0290","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/neuonc\/noq202","article-title":"Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas","volume":"13","author":"Haas-Kogan","year":"2011","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0295","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4143\/crt.2021.1514","article-title":"Suggestions for escaping the dark ages for pediatric diffuse intrinsic pontine glioma treated with radiotherapy: analysis of prognostic factors from the National Multicenter Study","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res. Treat."},{"issue":"7","key":"10.1016\/j.jconrel.2024.05.018_bb0300","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3390\/pharmaceutics12070660","article-title":"Convection enhanced delivery for diffuse intrinsic pontine glioma: review of a single institution experience","volume":"12","author":"Tosi","year":"2020","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.jconrel.2024.05.018_bb0305","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/neuonc\/noy070","article-title":"Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma","volume":"20","author":"Gupta","year":"2018","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jconrel.2024.05.018_bb0310","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2019.03.019","article-title":"Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience","volume":"114","author":"Pfaff","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.jconrel.2024.05.018_bb0315","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nm.3855","article-title":"Functionally defined therapeutic targets in diffuse intrinsic pontine glioma","volume":"21","author":"Grasso","year":"2015","journal-title":"Nat. Med."},{"issue":"18","key":"10.1016\/j.jconrel.2024.05.018_bb0320","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1158\/1078-0432.CCR-22-0803","article-title":"Upfront biology-guided therapy in diffuse intrinsic pontine glioma: therapeutic, molecular, and biomarker outcomes from PNOC003","volume":"28","author":"Kline","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0325","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10143-019-01234-w","article-title":"Complications after frame-based stereotactic brain biopsy: a systematic review","volume":"44","author":"Riche","year":"2021","journal-title":"Neurosurg. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0330","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(06)70615-5","article-title":"Diffuse brainstem glioma in children: critical review of clinical trials","volume":"7","author":"Hargrave","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0335","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-017-0004-3","article-title":"Controlled drug delivery vehicles for cancer treatment and their performance","volume":"3","author":"Senapati","year":"2018","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.jconrel.2024.05.018_bb0340","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1517\/17425240903167942","article-title":"New strategies to deliver anticancer drugs to brain tumors","volume":"6","author":"Laquintana","year":"2009","journal-title":"Expert Opin. Drug Deliv."},{"issue":"6","key":"10.1016\/j.jconrel.2024.05.018_bb0345","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/19491034.2015.1107689","article-title":"Chromatin structure and gene regulation: a dynamic view of enhancer function","volume":"6","author":"Stavreva","year":"2015","journal-title":"Nucleus"},{"issue":"8","key":"10.1016\/j.jconrel.2024.05.018_bb0350","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0355","doi-asserted-by":"crossref","first-page":"2124058","DOI":"10.1080\/2162402X.2022.2124058","article-title":"Immunotherapy approaches for the treatment of diffuse midline gliomas","volume":"11","author":"Bernstock","year":"2022","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.jconrel.2024.05.018_bb0360","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/neuonc\/noaa126","article-title":"Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors","volume":"22","author":"Wongthida","year":"2020","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0365","article-title":"HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma","volume":"5","author":"Wang","year":"2023","journal-title":"Neurooncol Adv."},{"issue":"14","key":"10.1016\/j.jconrel.2024.05.018_bb0370","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1158\/0008-5472.CAN-23-0186","article-title":"ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma","volume":"83","author":"Jackson","year":"2023","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0375","article-title":"Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma","volume":"3","author":"Duchatel","year":"2021","journal-title":"Neurooncol Adv."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0380","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41467-021-20896-z","article-title":"Dual targeting of polyamine synthesis and uptake in diffuse intrinsic pontine gliomas","volume":"12","author":"Khan","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.jconrel.2024.05.018_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108994","article-title":"Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG","volume":"35","author":"Ehteda","year":"2021","journal-title":"Cell Rep."},{"issue":"519","key":"10.1016\/j.jconrel.2024.05.018_bb0390","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw0064","article-title":"Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening","volume":"11","author":"Lin","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0395","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ebiom.2019.04.043","article-title":"Potent anti-tumor efficacy of palbociclib in treatment-na\u00efve H3.3K27M-mutant diffuse intrinsic pontine glioma","volume":"43","author":"Sun","year":"2019","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.jconrel.2024.05.018_bb0400","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","article-title":"Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas","volume":"24","author":"Mount","year":"2018","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0405","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/neuonc\/noac141","article-title":"Therapeutic targeting of prenatal pontine ID1 signaling in diffuse midline glioma","volume":"25","author":"Messinger","year":"2023","journal-title":"Neuro-Oncology"},{"issue":"10","key":"10.1016\/j.jconrel.2024.05.018_bb0410","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1172\/JCI133310","article-title":"Everolimus improves the efficacy of dasatinib in PDGFR\u03b1-driven glioma","volume":"130","author":"Miklja","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0415","first-page":"381","article-title":"Generation of diffuse intrinsic pontine glioma mouse models by brainstem-targeted in utero electroporation","volume":"22","author":"Patel","year":"2020","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jconrel.2024.05.018_bb0420","first-page":"9","article-title":"Current murine models and new developments in H3K27M diffuse midline gliomas","author":"Welby","year":"2019","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0425","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-023-04323-5","article-title":"A novel CDK4\/6 inhibitor combined with irradiation demonstrates potent anti-tumor efficacy in diffuse midline glioma","volume":"163","author":"Zuo","year":"2023","journal-title":"J. Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0430","article-title":"An EZH2 blocker sensitizes histone mutated diffuse midline glioma to cholesterol metabolism inhibitors through an off-target effect","volume":"4","author":"Rahal","year":"2022","journal-title":"Neuro-Oncol. Adv."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0435","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40478-022-01336-5","article-title":"A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis","volume":"10","author":"Dhar","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0440","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s40478-021-01270-y","article-title":"TP53 wild-type\/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist","volume":"9","author":"Xu","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0445","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ccell.2020.02.002","article-title":"Mutant ACVR1 arrests glial cell differentiation to drive tumorigenesis in pediatric gliomas","volume":"37","author":"Fortin","year":"2020","journal-title":"Cancer Cell"},{"issue":"691","key":"10.1016\/j.jconrel.2024.05.018_bb0450","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add8280","article-title":"Antisense oligonucleotide therapy for H3.3K27M diffuse midline glioma","volume":"15","author":"Zhang","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0455","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1002\/1878-0261.13427","article-title":"Targeting mitochondrial energetics reverses panobinostat- and marizomib-induced resistance in pediatric and adult high-grade gliomas","volume":"17","author":"Jane","year":"2023","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0460","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1158\/2159-8290.CD-20-1201","article-title":"Repurposing Vandetanib plus Everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma","volume":"12","author":"Carvalho","year":"2021","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0465","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1186\/s12967-020-02593-5","article-title":"OKlahoma Nitrone-007: novel treatment for diffuse intrinsic pontine glioma","volume":"18","author":"Thomas","year":"2020","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0470","first-page":"156","article-title":"ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma","volume":"2","author":"Carvalho","year":"2019","journal-title":"Communicat. Biol."},{"issue":"7","key":"10.1016\/j.jconrel.2024.05.018_bb0475","doi-asserted-by":"crossref","first-page":"7541","DOI":"10.18632\/oncotarget.24045","article-title":"Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma","volume":"9","author":"Tsoli","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0480","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1084\/jem.20171046","article-title":"Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy","volume":"215","author":"Chheda","year":"2018","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0485","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11060-017-2681-8","article-title":"New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model","volume":"136","author":"Louis","year":"2018","journal-title":"J. Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0490","article-title":"Overcoming translational barriers in H3K27-altered diffuse midline glioma: increasing the drug-tumor residence time","volume":"5","author":"Power","year":"2023","journal-title":"Neurooncol Adv."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0495","doi-asserted-by":"crossref","first-page":"1101522","DOI":"10.3389\/fonc.2023.1101522","article-title":"Addressing blood-brain-tumor-barrier heterogeneity in pediatric brain tumors with innovative preclinical models","volume":"13","author":"Morris","year":"2023","journal-title":"Front. Oncol."},{"issue":"7\u20138","key":"10.1016\/j.jconrel.2024.05.018_bb0500","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1101\/gad.309823.117","article-title":"Bridging barriers: a comparative look at the blood-brain barrier across organisms","volume":"32","author":"O\u2019Brown","year":"2018","journal-title":"Genes Dev."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2022.102330","article-title":"Mice in translational neuroscience: what R we doing?","volume":"217","author":"Azkona","year":"2022","journal-title":"Prog. Neurobiol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccell.2023.11.002","article-title":"A road map for the treatment of pediatric diffuse midline glioma","volume":"42","author":"Koschmann","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0515","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","article-title":"Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety","volume":"13","author":"Vitanza","year":"2023","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.jconrel.2024.05.018_bb0520","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.154812","article-title":"Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas","volume":"7","author":"Laspidea","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0525","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41467-019-10043-0","article-title":"The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models","volume":"10","author":"Martinez-Velez","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0530","first-page":"5","article-title":"Animal models in translational medicine: validation and prediction","volume":"2","author":"Denayer","year":"2014","journal-title":"New Horiz. Translat. Med."},{"issue":"8","key":"10.1016\/j.jconrel.2024.05.018_bb0535","first-page":"1","article-title":"Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice","volume":"50","author":"Choi","year":"2018","journal-title":"Exp. Mol. Med."},{"issue":"7","key":"10.1016\/j.jconrel.2024.05.018_bb0540","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1111\/cas.14934","article-title":"Development of humanized mouse with patient-derived xenografts for cancer immunotherapy studies: a comprehensive review","volume":"112","author":"Jin","year":"2021","journal-title":"Cancer Sci."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0545","doi-asserted-by":"crossref","first-page":"1145706","DOI":"10.3389\/fimmu.2023.1145706","article-title":"Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas","volume":"14","author":"Zuo","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.jconrel.2024.05.018_bb0550","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003816","article-title":"Targeting of the alpha(v) beta(3) integrin complex by CAR-T cells leads to rapid regression of diffuse intrinsic pontine glioma and glioblastoma","volume":"10","author":"Cobb","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.jconrel.2024.05.018_bb0555","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/neuonc\/noab300","article-title":"Dual IGF1R\/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant","volume":"24","author":"de Billy","year":"2022","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0560","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40478-019-0714-6","article-title":"Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models","volume":"7","author":"Martinez-Velez","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"issue":"6","key":"10.1016\/j.jconrel.2024.05.018_bb0565","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-20-1499","article-title":"Mesenchymal stem cells successfully deliver oncolytic Virotherapy to diffuse intrinsic pontine glioma","volume":"27","author":"Chastkofsky","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0570","article-title":"Generation of immunocompetent syngeneic allograft mouse models for pediatric diffuse midline glioma","volume":"4","author":"du Chatinier","year":"2022","journal-title":"Neurooncol Adv."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0575","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1186\/s12951-022-01610-7","article-title":"Overcoming the blood\u2013brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches","volume":"20","author":"Mitusova","year":"2022","journal-title":"J. Nanobiotechnol."},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0580","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11910-008-0036-8","article-title":"Drug delivery to brain tumors","volume":"8","author":"Blakeley","year":"2008","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0585","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s40478-022-01463-z","article-title":"Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma","volume":"10","author":"Zhao","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"issue":"10","key":"10.1016\/j.jconrel.2024.05.018_bb0590","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/neuonc\/noac093","article-title":"STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma","volume":"24","author":"Zhang","year":"2022","journal-title":"Neuro-Oncology"},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0595","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1158\/2159-8290.CD-20-0930","article-title":"DIPG harbors alterations targetable by MEK inhibitors, with acquired resistance mechanisms overcome by combinatorial inhibition","volume":"12","author":"Izquierdo","year":"2022","journal-title":"Cancer Discov."},{"issue":"14","key":"10.1016\/j.jconrel.2024.05.018_bb0600","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1158\/0008-5472.CAN-17-3691","article-title":"Dual HDAC and PI3K inhibition abrogates NF\u03baB- and FOXM1-mediated DNA damage response to Radiosensitize pediatric high-grade gliomas","volume":"78","author":"Pal","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0605","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.brainresbull.2022.09.017","article-title":"The barrier and interface mechanisms of the brain barrier, and brain drug delivery","volume":"190","author":"Zhang","year":"2022","journal-title":"Brain Res. Bull."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0610","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0615","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2015.00032","article-title":"Development of the choroid plexus and blood-CSF barrier","volume":"9","author":"Liddelow","year":"2015","journal-title":"Front. Neurosci."},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0620","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1517\/17425240903540205","article-title":"Central nervous system delivery of large molecules: challenges and new frontiers for intrathecally administered therapeutics","volume":"7","author":"Soderquist","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0625","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00401-018-1807-1","article-title":"Molecular anatomy and functions of the choroidal blood-cerebrospinal fluid barrier in health and disease","volume":"135","author":"Ghersi-Egea","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0630","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2045-8118-8-7","article-title":"Drug transport in brain via the cerebrospinal fluid","volume":"8","author":"Pardridge","year":"2011","journal-title":"Fluids Barriers CNS."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0635","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fnins.2015.00075","article-title":"Outer brain barriers in rat and human development","volume":"9","author":"Br\u00f8chner","year":"2015","journal-title":"Front. Neurosci."},{"issue":"10","key":"10.1016\/j.jconrel.2024.05.018_bb0640","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41573-022-00500-9","article-title":"The glymphatic system: implications for drugs for central nervous system diseases","volume":"21","author":"Lohela","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.jconrel.2024.05.018_bb0645","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1021\/mp300495e","article-title":"Diffusion of macromolecules in the brain: implications for drug delivery","volume":"10","author":"Wolak","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0650","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fnins.2015.00021","article-title":"Efflux transporters in blood-brain interfaces of the developing brain","volume":"9","author":"Strazielle","year":"2015","journal-title":"Front. Neurosci."},{"issue":"7","key":"10.1016\/j.jconrel.2024.05.018_bb0655","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1073\/pnas.96.7.3900","article-title":"Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier","volume":"96","author":"Rao","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.jconrel.2024.05.018_bb0660","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1080\/17425255.2018.1513493","article-title":"Impact of transporters and enzymes from blood\u2013cerebrospinal fluid barrier and brain parenchyma on CNS drug uptake","volume":"14","author":"Wang","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0665","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1046\/j.1471-4159.1994.62031089.x","article-title":"Localization of drug-metabolizing enzyme activities to blood-brain interfaces and circumventricular organs","volume":"62","author":"Ghersi-Egea","year":"1994","journal-title":"J. Neurochem."},{"issue":"17","key":"10.1016\/j.jconrel.2024.05.018_bb0670","doi-asserted-by":"crossref","first-page":"7612","DOI":"10.1128\/MCB.24.17.7612-7621.2004","article-title":"Mrp4 confers resistance to topotecan and protects the brain from chemotherapy","volume":"24","author":"Leggas","year":"2004","journal-title":"Mol. Cell. Biol."},{"issue":"8","key":"10.1016\/j.jconrel.2024.05.018_bb0675","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.3390\/pharmaceutics14081729","article-title":"In vitro models of the blood-cerebrospinal fluid barrier and their applications in the development and research of (neuro)pharmaceuticals","volume":"14","author":"Dabbagh","year":"2022","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0680","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1208\/s12248-021-00587-9","article-title":"Choroid plexus and drug removal mechanisms","volume":"23","author":"Sun","year":"2021","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0685","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/2045-8118-10-25","article-title":"Developmental changes in the transcriptome of the rat choroid plexus in relation to neuroprotection","volume":"10","author":"Kratzer","year":"2013","journal-title":"Fluids Barriers CNS."},{"issue":"14","key":"10.1016\/j.jconrel.2024.05.018_bb0690","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1523\/JNEUROSCI.2967-17.2018","article-title":"Glutathione conjugation at the blood-CSF barrier efficiently prevents exposure of the developing brain fluid environment to blood-borne reactive electrophilic substances","volume":"38","author":"Kratzer","year":"2018","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.jconrel.2024.05.018_bb0695","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1124\/dmd.112.050344","article-title":"Drug transporters on arachnoid barrier cells contribute to the blood\u2013cerebrospinal fluid barrier","volume":"41","author":"Yasuda","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0700","article-title":"Living on the edge of the CNS: meninges cell diversity in Health and disease","volume":"15","author":"Derk","year":"2021","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0705","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.732820","article-title":"The \u201cneuro-glial-vascular\u201d unit: the role of glia in neurovascular unit formation and dysfunction","volume":"9","author":"Kugler","year":"2021","journal-title":"Front. Cell Develop. Biol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0710","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2003.12.016","article-title":"The blood-brain barrier: an overview: structure, regulation, and clinical implications","volume":"16","author":"Ballabh","year":"2004","journal-title":"Neurobiol. Dis."},{"issue":"6","key":"10.1016\/j.jconrel.2024.05.018_bb0715","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.3390\/cells10061400","article-title":"Role of intermediate filaments in blood-brain barrier in Health and disease","volume":"10","author":"Bayir","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0720","doi-asserted-by":"crossref","first-page":"1904773","DOI":"10.1080\/21688370.2021.1904773","article-title":"Surface charge, glycocalyx, and blood-brain barrier function","volume":"9","author":"Walter","year":"2021","journal-title":"Tissue Barr."},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0725","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.bbamem.2007.07.012","article-title":"Adherens and tight junctions: structure, function and connections to the actin cytoskeleton","volume":"1778","author":"Hartsock","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2024.05.018_bb0730","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.00914","article-title":"Structure, function, and regulation of the blood-brain barrier tight junction in central nervous system disorders","volume":"11","author":"Lochhead","year":"2020","journal-title":"Front. Physiol."},{"issue":"6","key":"10.1016\/j.jconrel.2024.05.018_bb0735","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nn.4288","article-title":"Pericytes of the neurovascular unit: key functions and signaling pathways","volume":"19","author":"Sweeney","year":"2016","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0740","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev.neuro.30.051606.094345","article-title":"Neuron-glial interactions in blood-brain barrier formation","volume":"30","author":"Banerjee","year":"2007","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0745","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jconrel.2022.08.051","article-title":"Recent advances in drug delivery and targeting to the brain","volume":"350","author":"Sethi","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.05.018_bb0750","first-page":"11","article-title":"Pathways for small molecule delivery to the central nervous system across the blood-brain barrier","volume":"6","author":"Mikitsh","year":"2014","journal-title":"Persp. Medicin. Chem."},{"issue":"10","key":"10.1016\/j.jconrel.2024.05.018_bb0755","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.2174\/13816128113199990463","article-title":"Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?","volume":"20","author":"Sanchez-Covarrubias","year":"2014","journal-title":"Curr. Pharm. Des."},{"issue":"7","key":"10.1016\/j.jconrel.2024.05.018_bb0760","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.3390\/ijms22073742","article-title":"Disease-induced modulation of drug transporters at the blood-brain barrier level","volume":"22","author":"Al Rihani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0765","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2018.01019","article-title":"Transcytosis to cross the blood brain barrier, new advancements and challenges","volume":"12","author":"Pulgar","year":"2019","journal-title":"Front. Neurosci."},{"issue":"2","key":"10.1016\/j.jconrel.2024.05.018_bb0770","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jphs.2019.12.008","article-title":"The solute carrier transporters and the brain: physiological and pharmacological implications","volume":"15","author":"Hu","year":"2020","journal-title":"Asian J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0775","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13041-022-00937-4","article-title":"Blood-brain barrier: emerging trends on transport models and new-age strategies for therapeutics intervention against neurological disorders","volume":"15","author":"Alajangi","year":"2022","journal-title":"Mol. Brain"},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0780","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1039\/D2BM01790C","article-title":"Harnessing nanobiotechnology for cerebral ischemic stroke management","volume":"11","author":"Tang","year":"2023","journal-title":"Biomater. Sci."},{"issue":"14","key":"10.1016\/j.jconrel.2024.05.018_bb0785","doi-asserted-by":"crossref","first-page":"1903759","DOI":"10.1002\/adma.201903759","article-title":"Sequential targeting in crosslinking Nanotheranostics for tackling the multibarriers of brain tumors","volume":"32","author":"Wu","year":"2020","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0790","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1080\/10717544.2018.1431978","article-title":"Dual-targeting for brain-specific drug delivery: synthesis and biological evaluation","volume":"25","author":"Yue","year":"2018","journal-title":"Drug Deliv."},{"issue":"11","key":"10.1016\/j.jconrel.2024.05.018_bb0795","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1021\/acs.molpharmaceut.7b00569","article-title":"Large amino acid transporter 1 selective liposomes of l-DOPA functionalized Amphiphile for combating glioblastoma","volume":"14","author":"Bhunia","year":"2017","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.jconrel.2024.05.018_bb0800","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3390\/pharmaceutics12040344","article-title":"L-type amino acid transporter 1-utilizing prodrugs of Ketoprofen can efficiently reduce brain prostaglandin levels","volume":"12","author":"Montaser","year":"2020","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.jconrel.2024.05.018_bb0805","first-page":"1605","article-title":"L-carnitine-conjugated nanoparticles to promote permeation across blood-brain barrier and to target glioma cells for drug delivery via the novel organic cation\/carnitine transporter OCTN2","volume":"46","author":"Kou","year":"2018","journal-title":"Artif Cells Nanomed. Biotechnol."},{"issue":"7","key":"10.1016\/j.jconrel.2024.05.018_bb0810","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s11095-022-03241-x","article-title":"Targeting transporters for drug delivery to the brain: can we do better?","volume":"39","author":"Puris","year":"2022","journal-title":"Pharm. Res."},{"issue":"6","key":"10.1016\/j.jconrel.2024.05.018_bb0815","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3390\/pharmaceutics14061234","article-title":"Increased\/targeted brain (pro)drug delivery via utilization of solute carriers (SLCs)","volume":"14","author":"Huttunen","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2024.05.018_bb0820","doi-asserted-by":"crossref","first-page":"25337","DOI":"10.3389\/fphar.2012.00074","article-title":"The role of ATP-binding cassette transporters in neuro-inflammation: relevance for bioactive lipids","volume":"3","author":"Kooij","year":"2012","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0825","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1602\/neurorx.2.1.86","article-title":"Blood-brain barrier active efflux transporters: ATP-binding cassette gene family","volume":"2","author":"L\u00f6scher","year":"2005","journal-title":"NeuroRx"},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0830","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1208\/s12248-008-9055-2","article-title":"CNS delivery via adsorptive transcytosis","volume":"10","author":"Herv\u00e9","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0835","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.conb.2018.12.014","article-title":"Transcytosis at the blood-brain barrier","volume":"57","author":"Ayloo","year":"2019","journal-title":"Curr. Opin. Neurobiol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0840","doi-asserted-by":"crossref","first-page":"10396","DOI":"10.1038\/s41598-017-11220-1","article-title":"Targeting transferrin receptors at the blood-brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma","volume":"7","author":"Johnsen","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0845","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","article-title":"Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle","volume":"81","author":"Niewoehner","year":"2014","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.jconrel.2024.05.018_bb0850","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/j.1471-4159.2008.05492.x","article-title":"Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2","volume":"106","author":"Demeule","year":"2008","journal-title":"J. Neurochem."},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0855","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0032568","article-title":"Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model","volume":"7","author":"Wagner","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jconrel.2024.05.018_bb0860","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/bit.21120","article-title":"Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier","volume":"96","author":"Boado","year":"2007","journal-title":"Biotechnol. Bioeng."},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0865","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1023\/A:1007592720793","article-title":"Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor","volume":"17","author":"Coloma","year":"2000","journal-title":"Pharm. Res."},{"issue":"7","key":"10.1016\/j.jconrel.2024.05.018_bb0870","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.3390\/pharmaceutics14071452","article-title":"Brain delivery of IGF1R5, a single-domain antibody targeting insulin-like growth factor-1 receptor","volume":"14","author":"Yogi","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0875","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1038\/s41598-021-83198-w","article-title":"Defining the epitope of a blood\u2013brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor","volume":"11","author":"Sheff","year":"2021","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.jconrel.2024.05.018_bb0880","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1016\/j.jconrel.2006.09.050","article-title":"A novel opportunity for targeted drug delivery to the brain","volume":"116","author":"Gaillard","year":"2006","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0885","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/17425247.2019.1583205","article-title":"Blood-brain barrier receptors and transporters: an insight on their function and how to exploit them through nanotechnology","volume":"16","author":"Moura","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0890","first-page":"335","article-title":"Drug and xenobiotic biotransformation in the blood\u2013brain barrier: a neglected issue","volume":"8","author":"Ag\u00fandez","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.jconrel.2024.05.018_bb0895","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.neuro.2021.08.004","article-title":"Xenobiotic transport and metabolism in the human brain","volume":"86","author":"Silva-Adaya","year":"2021","journal-title":"NeuroToxicology"},{"issue":"6","key":"10.1016\/j.jconrel.2024.05.018_bb0900","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/j.1471-4159.2008.05720.x","article-title":"ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood\u2013brain barrier","volume":"107","author":"Dauchy","year":"2008","journal-title":"J. Neurochem."},{"issue":"4","key":"10.1016\/j.jconrel.2024.05.018_bb0905","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1021\/mp200129p","article-title":"Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels","volume":"8","author":"Shawahna","year":"2011","journal-title":"Mol. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0910","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/138920013804545232","article-title":"Hurdles with using in vitro models to predict human blood-brain barrier drug permeability: a special focus on transporters and metabolizing enzymes","volume":"14","author":"Shawahna","year":"2013","journal-title":"Curr. Drug Metab."},{"issue":"7","key":"10.1016\/j.jconrel.2024.05.018_bb0915","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1124\/dmd.109.027011","article-title":"Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function","volume":"37","author":"Dutheil","year":"2009","journal-title":"Drug Metab. Dispos."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0920","article-title":"Heterogeneity of the blood-brain barrier","volume":"4","author":"Wilhelm","year":"2016","journal-title":"Tissue Barr."},{"issue":"4","key":"10.1016\/j.jconrel.2024.05.018_bb0925","first-page":"355","article-title":"Model for concomitant microdialysis sampling of the pons and cerebral cortex in rhesus macaques (Macaca mulatta)","volume":"63","author":"McCully","year":"2013","journal-title":"Comp. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0930","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0026-2862(85)90042-1","article-title":"Morphometric analysis of CNS microvascular endothelium","volume":"30","author":"Coomber","year":"1985","journal-title":"Microvasc. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0935","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.3171\/2015.1.FOCUS14767","article-title":"Novel delivery methods bypassing the blood-brain and blood-tumor barriers","volume":"38","author":"Hendricks","year":"2015","journal-title":"Neurosurg. Focus FOC."},{"issue":"10","key":"10.1016\/j.jconrel.2024.05.018_bb0940","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.7150\/thno.69682","article-title":"Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy","volume":"12","author":"Upton","year":"2022","journal-title":"Theranostics"},{"issue":"23","key":"10.1016\/j.jconrel.2024.05.018_bb0945","doi-asserted-by":"crossref","first-page":"12654","DOI":"10.3390\/ijms222312654","article-title":"Blood-brain barrier in brain tumors: biology and clinical relevance","volume":"22","author":"Mo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.jconrel.2024.05.018_bb0950","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00415-017-8695-5","article-title":"Advances in immunotherapeutic research for glioma therapy","volume":"265","author":"Miyauchi","year":"2018","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.jconrel.2024.05.018_bb0955","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.3390\/cancers13102391","article-title":"Breaching the blood-brain tumor barrier for tumor therapy","volume":"13","author":"Marcucci","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0960","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00381-017-3659-8","article-title":"T2-weighted images are superior to other MR image types for the determination of diffuse intrinsic pontine glioma intratumoral heterogeneity","volume":"34","author":"Harward","year":"2018","journal-title":"Childs Nerv. Syst."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0965","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s41231-022-00115-7","article-title":"Imaged-guided focused ultrasound in combination with various formulations of doxorubicin for the treatment of diffuse intrinsic pontine glioma","volume":"7","author":"Haumann","year":"2022","journal-title":"Translat. Med. Communicat."},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0970","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41551-018-0334-7","article-title":"Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium","volume":"3","author":"Seano","year":"2019","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0975","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s40478-021-01243-1","article-title":"Defining tumor-associated vascular heterogeneity in pediatric high-grade and diffuse midline gliomas","volume":"9","author":"Wei","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb0980","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.3892\/etm.2016.3557","article-title":"Plasmalemma vesicle-associated protein: a crucial component of vascular homeostasis","volume":"12","author":"Guo","year":"2016","journal-title":"Exp. Ther. Med."},{"issue":"5","key":"10.1016\/j.jconrel.2024.05.018_bb0985","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3390\/pharmaceutics12050399","article-title":"Characterization of the blood-brain barrier integrity and the brain transport of SN-38 in an Orthotopic xenograft rat model of diffuse intrinsic pontine glioma","volume":"12","author":"Chaves","year":"2020","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.jconrel.2024.05.018_bb0990","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061512","article-title":"In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma","volume":"8","author":"Veringa","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb0995","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12987-020-00198-0","article-title":"Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance","volume":"17","author":"Deligne","year":"2020","journal-title":"Fluids Barriers CNS."},{"issue":"8","key":"10.1016\/j.jconrel.2024.05.018_bb1000","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.bcp.2009.06.001","article-title":"Regional differences in capillary density, perfusion rate, and P-glycoprotein activity: a quantitative analysis of regional drug exposure in the brain","volume":"78","author":"Zhao","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.05.018_bb1005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jconrel.2018.05.005","article-title":"Brainstem blood brain barrier disruption using focused ultrasound: a demonstration of feasibility and enhanced doxorubicin delivery","volume":"281","author":"Alli","year":"2018","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.jconrel.2024.05.018_bb1010","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11060-015-1969-9","article-title":"Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma","volume":"126","author":"Subashi","year":"2016","journal-title":"J. Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb1015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40478-018-0553-x","article-title":"Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma","volume":"6","author":"Lin","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb1020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/neuonc\/noy145","article-title":"Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy","volume":"21","author":"Lieberman","year":"2019","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb1025","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","article-title":"Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence","volume":"25","author":"Klempner","year":"2020","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb1030","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2174\/1570159X14666160614093615","article-title":"Convection-enhanced delivery for diffuse intrinsic pontine glioma treatment","volume":"15","author":"Zhou","year":"2017","journal-title":"Curr. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.jconrel.2024.05.018_bb1035","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3390\/ijms18020351","article-title":"Advances in molecular imaging of locally delivered targeted therapeutics for central nervous system tumors","volume":"18","author":"Tosi","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.jconrel.2024.05.018_bb1040","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1021\/acschemneuro.8b00607","article-title":"Real-time, in vivo correlation of molecular structure with drug distribution in the brain striatum following convection enhanced delivery","volume":"10","author":"Tosi","year":"2019","journal-title":"ACS Chem. Neurosci."},{"issue":"2","key":"10.1016\/j.jconrel.2024.05.018_bb1045","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1021\/acsmedchemlett.7b00471","article-title":"18F-radiolabeled Panobinostat allows for positron emission tomography guided delivery of a histone deacetylase inhibitor","volume":"9","author":"Kommidi","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"issue":"11","key":"10.1016\/j.jconrel.2024.05.018_bb1050","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s40263-020-00766-w","article-title":"Overview of current drug delivery methods across the blood-brain barrier for the treatment of primary brain tumors","volume":"34","author":"Haumann","year":"2020","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.jconrel.2024.05.018_bb1055","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s13311-017-0520-4","article-title":"Convection-enhanced delivery","volume":"14","author":"Mehta","year":"2017","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.jconrel.2024.05.018_bb1060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fonc.2019.00031","article-title":"Treatment strategies in diffuse midline gliomas with the H3K27M mutation: the role of convection-enhanced delivery in overcoming anatomic challenges","volume":"9","author":"Himes","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jconrel.2024.05.018_bb1065","doi-asserted-by":"crossref","first-page":"966","DOI":"10.3389\/fonc.2019.00966","article-title":"Convection-enhanced delivery: connection to and impact of interstitial fluid flow","volume":"9","author":"Stine","year":"2019","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.jconrel.2024.05.018_bb1070","doi-asserted-by":"crossref","first-page":"457","DOI":"10.4155\/tde-2016-0016","article-title":"Delivering therapy to target: improving the odds for successful drug development","volume":"7","author":"Raghavan","year":"2016","journal-title":"Ther. Deliv."},{"issue":"2","key":"10.1016\/j.jconrel.2024.05.018_bb1075","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000342492","article-title":"Pathways of infusate loss during convection-enhanced delivery into the putamen nucleus","volume":"91","author":"Brady","year":"2013","journal-title":"Stereotact. Funct. Neurosurg."},{"issue":"4","key":"10.1016\/j.jconrel.2024.05.018_bb1080","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3390\/pharmaceutics13040561","article-title":"Convection enhanced delivery in the setting of high-grade gliomas","volume":"13","author":"Nwagwu","year":"2021","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb1085","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3171\/JNS\/2008\/109\/9\/0547","article-title":"Effect of ependymal and pial surfaces on convection-enhanced delivery","volume":"109","author":"Jagannathan","year":"2008","journal-title":"J. Neurosurg."},{"issue":"5","key":"10.1016\/j.jconrel.2024.05.018_bb1090","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.3171\/2015.4.JNS132778","article-title":"Microsurgical anatomy and internal architecture of the brainstem in 3D images: surgical considerations","volume":"124","author":"P\u00e1rraga","year":"2016","journal-title":"J. Neurosurg."},{"issue":"2","key":"10.1016\/j.jconrel.2024.05.018_bb1095","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3171\/2010.2.JNS091744","article-title":"Cannula placement for effective convection-enhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics","volume":"113","author":"Yin","year":"2010","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.jconrel.2024.05.018_bb1100","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114303","article-title":"Drug delivery across the blood-brain barrier for the treatment of pediatric brain tumors \u2013 An update","volume":"185","author":"Power","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.jconrel.2024.05.018_bb1105","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00401-014-1307-x","article-title":"Subventricular spread of diffuse intrinsic pontine glioma","volume":"128","author":"Caretti","year":"2014","journal-title":"Acta Neuropathol."},{"issue":"2","key":"10.1016\/j.jconrel.2024.05.018_bb1110","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11060-022-04077-6","article-title":"Infusion-related side-effects during convection enhanced delivery for brainstem-diffuse midline glioma\/diffuse intrinsic pontine glioma","volume":"159","author":"Hollingworth","year":"2022","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jconrel.2024.05.018_bb1115","doi-asserted-by":"crossref","first-page":"9342796","DOI":"10.1155\/2019\/9342796","article-title":"Convection-enhanced delivery in malignant gliomas: a review of toxicity and efficacy","volume":"2019","author":"Shi","year":"2019","journal-title":"J. Oncol."},{"key":"10.1016\/j.jconrel.2024.05.018_bb1120","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.addr.2014.01.008","article-title":"Ultrasound-mediated blood\u2013brain barrier disruption for targeted drug delivery in the central nervous system","volume":"72","author":"Aryal","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.05.018_bb1125","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jconrel.2019.07.023","article-title":"Safety and efficacy of focused ultrasound induced blood-brain barrier opening, an integrative review of animal and human studies","volume":"309","author":"Meng","year":"2019","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb1130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41582-020-00418-z","article-title":"Applications of focused ultrasound in the brain: from thermoablation to drug delivery","volume":"17","author":"Meng","year":"2021","journal-title":"Nat. Rev. Neurol."},{"issue":"37","key":"10.1016\/j.jconrel.2024.05.018_bb1135","doi-asserted-by":"crossref","first-page":"E8717","DOI":"10.1073\/pnas.1807105115","article-title":"Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood\u2013tumor barrier disruption","volume":"115","author":"Arvanitis","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"14","key":"10.1016\/j.jconrel.2024.05.018_bb1140","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1158\/0008-5472.CAN-12-0128","article-title":"Temporary disruption of the blood\u2013brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques","volume":"72","author":"McDannold","year":"2012","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.jconrel.2024.05.018_bb1145","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1021\/cn300191b","article-title":"Noninvasive and targeted drug delivery to the brain using focused ultrasound","volume":"4","author":"Burgess","year":"2013","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb1150","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1038\/s41598-021-85180-y","article-title":"Focused ultrasound mediated blood\u2013brain barrier opening is safe and feasible in a murine pontine glioma model","volume":"11","author":"Englander","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2024.05.018_bb1155","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100876","article-title":"Past, present and future of focused ultrasound as an adjunct or complement to DIPG\/DMG therapy: a consensus of the 2021 FUSF DIPG meeting","volume":"37","author":"Parekh","year":"2023","journal-title":"Neoplasia"},{"issue":"9","key":"10.1016\/j.jconrel.2024.05.018_bb1160","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.4049\/jimmunol.1901430","article-title":"Focused ultrasound for immunomodulation of the tumor microenvironment","volume":"205","author":"Joiner","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2024.05.018_bb1165","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.jconrel.2020.11.010","article-title":"MRI-guided focused ultrasound enhances drug delivery in experimental diffuse intrinsic pontine glioma","volume":"330","author":"Ishida","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.05.018_bb1170","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jconrel.2023.03.058","article-title":"Radiosensitisation by olaparib through focused ultrasound delivery in a diffuse midline glioma model","volume":"357","author":"\u2019t Hart","year":"2023","journal-title":"J. Control. Release"},{"issue":"21","key":"10.1016\/j.jconrel.2024.05.018_bb1175","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.7150\/thno.35892","article-title":"Acoustic feedback enables safe and reliable carboplatin delivery across the blood-brain barrier with a clinical focused ultrasound system and improves survival in a rat glioma model","volume":"9","author":"McDannold","year":"2019","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb1180","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41597-021-01069-5","article-title":"A curated diverse molecular database of blood-brain barrier permeability with chemical descriptors","volume":"8","author":"Meng","year":"2021","journal-title":"Sci. Data."},{"issue":"5","key":"10.1016\/j.jconrel.2024.05.018_bb1185","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1818","article-title":"Brain-targeting drug delivery systems","volume":"14","author":"Liu","year":"2022","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb1190","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12967-024-05096-9","article-title":"Focused ultrasound-mediated blood-brain barrier opening is safe and feasible with moderately hypofractionated radiotherapy for brainstem diffuse midline glioma","volume":"22","author":"Tazhibi","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.05.018_bb1195","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.903059","article-title":"Low-intensity focused ultrasound technique in glioblastoma Multiforme treatment","volume":"12","author":"Mungur","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb1200","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12951-023-01775-9","article-title":"Customizing delivery nano-vehicles for precise brain tumor therapy","volume":"21","author":"Miao","year":"2023","journal-title":"J. Nanobiotechnol."},{"issue":"6","key":"10.1016\/j.jconrel.2024.05.018_bb1205","first-page":"1","article-title":"Intranasal delivery of nanoliposomal SN-38 for treatment of diffuse midline glioma","volume":"138","author":"Sasaki","year":"2022","journal-title":"J. Neurosurg."},{"issue":"21","key":"10.1016\/j.jconrel.2024.05.018_bb1210","doi-asserted-by":"crossref","first-page":"2200353","DOI":"10.1002\/advs.202200353","article-title":"Functionalized macrophage exosomes with Panobinostat and PPM1D-siRNA for diffuse intrinsic pontine gliomas therapy","volume":"9","author":"Shan","year":"2022","journal-title":"Adv. Sci."},{"issue":"6","key":"10.1016\/j.jconrel.2024.05.018_bb1215","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3390\/cancers13061278","article-title":"Doxorubicin-loaded gold Nanoarchitectures as a therapeutic strategy against diffuse intrinsic pontine glioma","volume":"13","author":"Ung","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.jconrel.2024.05.018_bb1220","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/neuonc\/noaa101","article-title":"A combined approach of convection-enhanced delivery of peptide nanofiber reservoir to prolong local DM1 retention for diffuse intrinsic pontine glioma treatment","volume":"22","author":"Bellat","year":"2020","journal-title":"Neuro-Oncology"},{"issue":"30","key":"10.1016\/j.jconrel.2024.05.018_bb1225","doi-asserted-by":"crossref","first-page":"35266","DOI":"10.1021\/acsami.1c04164","article-title":"Chemosensitization of Temozolomide-resistant pediatric diffuse midline glioma using potent Nanoencapsulated forms of a N(3)-Propargyl analogue","volume":"13","author":"Heravi Shargh","year":"2021","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2024.05.018_bb1230","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3389\/fphar.2018.00790","article-title":"Current trends and challenges in the clinical translation of Nanoparticulate nanomedicines: pathways for translational development and commercialization","volume":"9","author":"Hua","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.05.018_bb1235","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and challenges of liposome assisted drug delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front. Pharmacol."},{"issue":"13\u201314","key":"10.1016\/j.jconrel.2024.05.018_bb1240","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.addr.2013.09.001","article-title":"Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities","volume":"65","author":"Kirtane","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.05.018_bb1245","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114115","article-title":"Nanomedicine for brain cancer","volume":"182","author":"Quader","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"11","key":"10.1016\/j.jconrel.2024.05.018_bb1250","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3390\/nano8110899","article-title":"Size limit and energy analysis of nanoparticles during wrapping process by membrane","volume":"8","author":"Meng","year":"2018","journal-title":"Nanomaterials (Basel)."},{"issue":"4","key":"10.1016\/j.jconrel.2024.05.018_bb1255","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.7150\/thno.41161","article-title":"Multimodal and multiscale optical imaging of nanomedicine delivery across the blood-brain barrier upon sonopermeation","volume":"10","author":"May","year":"2020","journal-title":"Theranostics"},{"issue":"12","key":"10.1016\/j.jconrel.2024.05.018_bb1260","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.3390\/pharmaceutics13122045","article-title":"Polymeric nanoparticles properties and brain delivery","volume":"13","author":"Ribovski","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb1265","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/diagnostics12010173","article-title":"Nanoparticles for diagnosis and target therapy in pediatric brain cancers","volume":"12","author":"Guido","year":"2022","journal-title":"Diagnostics (Basel)."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb1270","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2174\/1570159X14666160223121002","article-title":"Nanotechnology applications for diffuse intrinsic pontine glioma","volume":"15","author":"Bredlau","year":"2017","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.jconrel.2024.05.018_bb1275","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","volume":"195","author":"Crowe","year":"2018","journal-title":"Life Sci."},{"issue":"4","key":"10.1016\/j.jconrel.2024.05.018_bb1280","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","article-title":"Intranasal drug delivery: opportunities and toxicologic challenges during drug development","volume":"12","author":"Keller","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2024.05.018_bb1285","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1021\/mp100029t","article-title":"Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures","volume":"7","author":"Johnson","year":"2010","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.jconrel.2024.05.018_bb1290","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.addr.2011.11.002","article-title":"Intranasal delivery of biologics to the central nervous system","volume":"64","author":"Lochhead","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.jconrel.2024.05.018_bb1295","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s40263-022-00930-4","article-title":"Using the intranasal route to administer drugs to treat neurological and psychiatric illnesses: rationale, successes, and future needs","volume":"36","author":"Lofts","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jconrel.2024.05.018_bb1300","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.626882","article-title":"Design and application in delivery system of intranasal antidepressants","volume":"8","author":"Xu","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb1305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2007.03.025","article-title":"Intranasal delivery: physicochemical and therapeutic aspects","volume":"337","author":"Costantino","year":"2007","journal-title":"Int. J. Pharm."},{"issue":"147","key":"10.1016\/j.jconrel.2024.05.018_bb1310","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003748","article-title":"A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid \u03b2","volume":"4","author":"Iliff","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2024.05.018_bb1315","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jconrel.2019.05.005","article-title":"Dexmedetomidine enhances glymphatic brain delivery of intrathecally administered drugs","volume":"304","author":"Lilius TO","year":"2019","journal-title":"J. Control. Release"},{"issue":"6156","key":"10.1016\/j.jconrel.2024.05.018_bb1320","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.1241224","article-title":"Sleep drives metabolite clearance from the adult brain","volume":"342","author":"Xie","year":"2013","journal-title":"Science"},{"issue":"46","key":"10.1016\/j.jconrel.2024.05.018_bb1325","doi-asserted-by":"crossref","first-page":"18190","DOI":"10.1523\/JNEUROSCI.1592-13.2013","article-title":"Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine brain","volume":"33","author":"Iliff","year":"2013","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.jconrel.2024.05.018_bb1330","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav5447","article-title":"Increased glymphatic influx is correlated with high EEG delta power and low heart rate in mice under anesthesia","volume":"5","author":"Hablitz","year":"2019","journal-title":"Sci. Adv."},{"issue":"9","key":"10.1016\/j.jconrel.2024.05.018_bb1335","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/WNR.0000000000000990","article-title":"Aquaporin-4 facilitator TGN-073 promotes interstitial fluid circulation within the blood-brain barrier: [17O]H2O JJVCPE MRI study","volume":"29","author":"Huber","year":"2018","journal-title":"Neuroreport"},{"key":"10.1016\/j.jconrel.2024.05.018_bb1340","doi-asserted-by":"crossref","first-page":"1179988","DOI":"10.3389\/fnagi.2023.1179988","article-title":"The glymphatic system: a new perspective on brain diseases","volume":"15","author":"Ding","year":"2023","journal-title":"Front. Aging Neurosci."},{"issue":"7","key":"10.1016\/j.jconrel.2024.05.018_bb1345","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.tins.2020.04.003","article-title":"The Brain\u2019s Glymphatic system: current controversies","volume":"43","author":"Mestre","year":"2020","journal-title":"Trends Neurosci."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb1350","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11060-014-1531-1","article-title":"Safety of Ommaya reservoirs in children with brain tumors: a 20-year experience with 5472 intraventricular drug administrations in 98 patients","volume":"120","author":"Peyrl","year":"2014","journal-title":"J. Neuro-Oncol."},{"issue":"7903","key":"10.1016\/j.jconrel.2024.05.018_bb1355","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.jconrel.2024.05.018_bb1360","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s00381-023-05950-z","article-title":"Intratumoral catheter placement in pediatric patients with diffuse midline gliomas","volume":"39","author":"Badaloni","year":"2023","journal-title":"Childs Nerv. Syst."},{"issue":"9","key":"10.1016\/j.jconrel.2024.05.018_bb1365","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.3390\/diagnostics12092064","article-title":"Pediatric diffuse midline gliomas: An unfinished puzzle","volume":"12","author":"Di Ruscio","year":"2022","journal-title":"Diagnostics (Basel)."},{"issue":"6","key":"10.1016\/j.jconrel.2024.05.018_bb1370","doi-asserted-by":"crossref","DOI":"10.1172\/JCI170329","article-title":"PI3K\/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma","volume":"134","author":"Duchatel","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.jconrel.2024.05.018_bb1375","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.ccell.2022.07.012","article-title":"A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma","volume":"40","author":"Pal","year":"2022","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.jconrel.2024.05.018_bb1380","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1158\/1078-0432.CCR-21-4002","article-title":"Venetoclax cooperates with ionizing radiation to attenuate diffuse midline glioma tumor growth","volume":"28","author":"Madhavan","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.jconrel.2024.05.018_bb1385","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/neuonc\/noab009","article-title":"Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma","volume":"23","author":"Katagi","year":"2021","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb1390","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.03.049","article-title":"Super elongation complex as a targetable dependency in diffuse midline glioma","volume":"31","author":"Dahl","year":"2020","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb1395","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/neuonc\/noz140","article-title":"Targeting reduced mitochondrial DNA quantity as a therapeutic approach in pediatric high-grade gliomas","volume":"22","author":"Shen","year":"2020","journal-title":"Neuro-Oncology"},{"issue":"13","key":"10.1016\/j.jconrel.2024.05.018_bb1400","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1158\/1078-0432.CCR-19-3538","article-title":"Combined therapy of AXL and HDAC inhibition reverses mesenchymal transition in diffuse intrinsic pontine glioma","volume":"26","author":"Meel","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.jconrel.2024.05.018_bb1405","doi-asserted-by":"crossref","first-page":"5572","DOI":"10.1158\/1078-0432.CCR-18-3890","article-title":"Radiosensitization by histone H3 demethylase inhibition in diffuse intrinsic pontine glioma","volume":"25","author":"Katagi","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.05.018_bb1410","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.canlet.2018.10.012","article-title":"Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal stem cell-based sTRAIL gene therapy against malignant glioma","volume":"442","author":"Choi","year":"2019","journal-title":"Cancer Lett."},{"issue":"22","key":"10.1016\/j.jconrel.2024.05.018_bb1415","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.1158\/1078-0432.CCR-18-0924","article-title":"MELK inhibition in diffuse intrinsic pontine glioma","volume":"24","author":"Meel","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.jconrel.2024.05.018_bb1420","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1158\/1078-0432.CCR-19-3714","article-title":"Therapeutic efficacy of immune stimulatory thymidine kinase and fms-like tyrosine kinase 3 ligand (TK\/Flt3L) gene therapy in a mouse model of high-grade brainstem glioma","volume":"26","author":"Mendez","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb1425","article-title":"MRI-guided focused ultrasound blood-brain barrier opening increases drug delivery and efficacy in a diffuse midline glioma mouse model","volume":"5","author":"Martinez","year":"2023","journal-title":"Neurooncol Adv."},{"issue":"5","key":"10.1016\/j.jconrel.2024.05.018_bb1430","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3390\/pharmaceutics14050922","article-title":"IL-13R\u03b12 status predicts GB-13 (IL13.E13K-PE4E) efficacy in high-grade glioma","volume":"14","author":"Rechberger","year":"2022","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.jconrel.2024.05.018_bb1435","doi-asserted-by":"crossref","first-page":"E680","DOI":"10.1093\/neuros\/nyaa301","article-title":"Convection-enhanced delivery of enhancer of Zeste Homolog-2 (EZH2) inhibitor for the treatment of diffuse intrinsic pontine glioma","volume":"87","author":"Sasaki","year":"2020","journal-title":"Neurosurgery"},{"issue":"5","key":"10.1016\/j.jconrel.2024.05.018_bb1440","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/neuros\/nyz212","article-title":"ABC transporter inhibition plus dexamethasone enhances the efficacy of convection enhanced delivery in H3.3K27M mutant diffuse intrinsic pontine glioma","volume":"86","author":"Tsvankin","year":"2020","journal-title":"Neurosurgery"},{"issue":"1","key":"10.1016\/j.jconrel.2024.05.018_bb1445","article-title":"Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy","volume":"1","author":"Chang","year":"2019","journal-title":"Neurooncol Adv."},{"issue":"5","key":"10.1016\/j.jconrel.2024.05.018_bb1450","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ccell.2019.09.005","article-title":"Re-programing chromatin with a bifunctional LSD1\/HDAC inhibitor induces therapeutic differentiation in DIPG","volume":"36","author":"Anastas","year":"2019","journal-title":"Cancer Cell"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592400302X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592400302X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T08:12:14Z","timestamp":1740211934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592400302X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":290,"alternative-id":["S016836592400302X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.05.018","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status and advances to improving drug delivery in diffuse intrinsic pontine glioma","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}